Share Prices & Company Research

Market News

29 Mar 2021 | 11:26

J&J to supply 400m Covid-19 vaccine doses to African Union

(Sharecast News) - Johnson & Johnson has agreed to supply member states of the African Vaccine Acquisition Trust with 400m dosis of its Covid-19 jab, the company said on Monday. The agreement with the African Union will make up to 220m doses of its single-shot vaccine candidate available to the bloc's 55 member states with delivery set to begin in the third quarter of 2021.

AVAT also has an option to order an additional 180m doses, for a combined total of up to 400m vials through 2022.

Availability of the vaccine candidate is subject to its successful approval or authorization by national regulatory authorities of AU member states, J&J said in a press release.

"From the beginning of this pandemic, Johnson & Johnson has recognized that no one is safe until everyone is safe, and we have been committed to equitable, global access to new Covid-19 vaccines," said Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson.

"Our support for the COVAX Facility, combined with supplementary agreements with countries and regions, will help accelerate global progress toward ending the Covid-19 pandemic."

Back in December 2020, J&J also entered into an agreement in principle with Gavi, the Vaccine Alliance (Gavi), in support of the COVAX Facility, which is supporting the initial vaccination needs of 190 participating economies, including many countries in Africa.

J&J and Gavi expect to enter into an Advance Purchase Agreement (APA) that would provide up to 500m doses of the Company's vaccine to COVAX through 2022.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.